Printing tool Download PDF


Feb 2007Oct 2007


Module 1: Initiate and provide structure for an entrepreneurial activity, to start a company, or manage a new activity within an existing structure (intrapreneurship activity).



Lille Flandres Artois University

Balloul JM, Sondermeyer P, Dreyer D, Capron M, Grzych JM, Pierce RJ, Carvallo D, Lecocq JP,. Capron A. (1987). Nature; 326 : 149.153.

Work experience


New Venture Development Director


Support  Transgene’s management to establish new ventures or to identify growth opportunities for Transgene: review business cases, seek additional information to confirm scientific and business rationale, structure scientific and development program.

Alliance Manager: Managing and developing new approach to strategic alliances and partnerships with key players in vaccine development.

Member of the In licensing Committee: analysis of opportunities that fit with strategic Company portfolio (

Novel active immunotherapy products, Adjuvant (to viral vectors and to proteins, Novel targets in infectious diseases, Novel tumor associated antigens).

Project leader of the Transgene Pharmaceutical Avian Cell Line Project dedicated to the production of therapeutic and prohylactic vaccines.


Head of Department

  • Operational Research Committe member
  • Management of three laboratories (Virology, Immunology and Biochemistry staff of 23 peoples scientists and technicians))
  • Molecular Biology and Virology (Poxvirus and Adenovirus)
  • Biochemistry
  • Expression systems (E coli, Yeast, eukaryotic cells)
  • Direction of the development of an avian cell line for vaccine production: Scientific coordination, Business Model development.

Group Leader

  • Development of the poxvirus platform (vaccine development, pox engineering)
  • HPV project leader for the development of a therapeutic vaccine against cervical cancer and high lesions associated with human papillomavirus infection
  • Head of the DNA sequencing lab


  • 1991-1998 HPV project leader for the development of a therapeutic vaccine against cervical cancer and high lesions associated with human papillomavirus infection
  • Head of the DNA sequencing lab
  • 1989-1991 Neuro immunology project leader (  Proteomic analysis of neuropepide stimulated T cells)

Research Assistant

Institut Pasteur de Lille
  • S. mansoni vaccine development Project Leader
  • Allergology Proteomic analysis


English semi-fluent

Spanish basic

Hebrew basic


2010: Niculescu Cristina; Balloul Jean-Marc A key for successful development of flu vaccines: Public-private collaboration - the Barcelona Vaccine Forum, Phacilitate, the Fira Palace Barcelona Spain, 21-23 June, 2010, the meeting report. Human vaccines 2010;6(12):966-9.Transgene, Boulevard Gonthier d'Andernach Illkirch, Graffenstaden, France.

2009: Tosch C; Geist M; Ledoux C; Ziller-Remi C; Paul S; Erbs P; Corvaia N; Von Hoegen P; Balloul J-M; Haegel HAdenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy.Cancer gene therapy 2009;16(4):310-9.Molecular Immunology Department, Transgene, Strasbourg, France. 2008: Foloppe J; Kintz J; Futin N; Findeli A; Cordier P; Schlesinger Y; Hoffmann C; Tosch C; Balloul J-M; Erbs PTargeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus.Gene therapy 2008;15(20):1361-71.Transgene SA, 11 rue de Molsheim, Strasbourg Cedex, France. 2008: Erbs P; Findeli A; Kintz J; Cordier P; Hoffmann C; Geist M; Balloul J-MModified vaccinia virus Ankara as a vector for suicide gene therapy.Cancer gene therapy 2008;15(1):18-28.Transgene S.A., 11 rue de Molsheim, Strasbourg Cedex, France. 2007: Paul Stéphane; Geist Michel; Dott Karine; Snary David; Taylor-Papadimitriou Joyce; Acres Bruce; Silvestre Nathalie; Kieny Marie-Paule; Balloul Jean-MarcSpecific tumor cell targeting by a recombinant MVA expressing a functional single chain antibody on the surface of intracellular mature virus (IMV) particles.Viral immunology 2007;20(4):664-71.Molecular Immunology Laboratory, Strasbourg, France. 2007: Fournillier A; Gerossier E; Evlashev A; Schmitt D; Simon B; Chatel L; Martin P; Silvestre N; Balloul J M; Barry R; Inchauspé GAn accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses.Vaccine 2007;25(42):7339-53.Transgene S.A., Site AFSSA, 31 avenue Tony Garnier, 69364 Lyon Cédex 07, France. 2005: Acres Bruce; Gantzer Murielle; Remy Christelle; Futin Nicolas; Accart Nathalie; Chaloin Olivier; Hoebeke Johan; Balloul Jean-Marc; Paul StéphaneFusokine interleukin-2/interleukin-18, a novel potent innate and adaptive immune stimulator with decreased toxicity.Cancer research 2005;65(20):9536-46.Division of Medical and Regulatory Affairs, Molecular Immunology Laboratory, Histology and Animal Facilities Laboratory, Transgene SA, Strasbourg, France. 2004: Liu Margaret; Acres Bruce; Balloul Jean-Marc; Bizouarne Nadine; Paul Stephane; Slos Philippe; Squiban PatrickGene-based vaccines and immunotherapeutics.Proceedings of the National Academy of Sciences of the United States of America 2004;101 Suppl 2():14567-71.Transgene, 11 Rue de Molsheim, 67082 Strasbourg, France. 2002: Paul Stephane; Regulier Etienne; Rooke Ronald; Stoeckel Fabienne; Geist Michel; Homann Horst; Balloul Jean-Marc; Villeval Dominique; Poitevin Yves; Kieny Marie-Paule; Acres R BruceTumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies.Cancer gene therapy 2002;9(5):470-7.Clinical and Experimental Immunology Laboratory, Transgene, Strasbourg 67082, France. 2001: Trevor K T; Hersh E M; Brailey J; Balloul J M; Acres BTransduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2.Cancer immunology, immunotherapy : CII 2001;50(8):397-407.Arizona Cancer Center, Tucson 85724, USA. 2000: Scholl S M; Balloul J M; Le Goc G; Bizouarne N; Schatz C; Kieny M P; von Mensdorff-Pouilly S; Vincent-Salomon A; Deneux L; Tartour E; Fridman W; Pouillart P; Acres BRecombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.Journal of immunotherapy (Hagerstown, Md. : 1997) 2000;23(5):570-80.Institut Curie, Département de Médecine Oncologique, Paris, France. 2000: Braun S; Thioudellet C; Rodriguez P; Ali-Hadji D; Perraud F; Accart N; Balloul J M; Halluard C; Acres B; Cavallini B; Pavirani AImmune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice.Gene therapy 2000;7(17):1447-57.Transgène S.A., Strasbourg, France. 2000: Paul S; Snary D; Hoebeke J; Allen D; Balloul J M; Bizouarne N; Dott K; Geist M; Hilgers J; Kieny M P; Burchell J; Taylor-Papadimitriou J; Acres R BTargeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment.Human gene therapy 2000;11(10):1417-28.Clinical and Experimental Immunology Laboratory, Transgene SA, Strasbourg, France. 2000: Spehner D; Drillien R; Proamer F; Houssais-Pêcheur C; Zanta M A; Geist M; Dott K; Balloul J MEnveloped virus is the major virus form produced during productive infection with the modified vaccinia virus Ankara strain.Virology 2000;273(1):9-15.Equipe Propre INSERM 99-08, Transgène, du Sang-Alsace, Strasbourg, France. 2000: Acres B; Apostolopoulos V; Balloul J M; Wreschner D; Xing P X; Ali-Hadji D; Bizouarne N; Kieny M P; McKenzie I FMUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines.Cancer immunology, immunotherapy : CII 2000;48(10):588-94.Department of Immunobiology, Transgène SA, Strasbourg, France. 1994: Balloul J M; Acres R B; Geist M; Dott K; Stefani L; Schmitt D; Drillien R; Spehner D; McKenzie I; Xing P XRecombinant MUC 1 vaccinia virus: a potential vector for immunotherapy of breast cancer.Cellular and molecular biology (Noisy-le-Grand, France) 1994;40 Suppl 1():49-59.INSERM U74, Université Louis Pasteur, Strasbourg, France. 1993: Acres R B; Hareuveni M; Balloul J M; Kieny M PVaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen.Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(2):136-43.Department of Immunology, Transgene S.A., Strasbourg, France. 1991: Boulanger D; Reid G D; Sturrock R F; Wolowczuk I; Balloul J M; Grezel D; Pierce R J; Otieno M F; Guerret S; Grimaud J AImmunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with Schistosoma mansoni.Parasite immunology 1991;13(5):473-90.Centre d'Immunologie et de Biologie Parasitaire, Unité Mixte INSERM 167-CNRS 624, Institut Pasteur, Lille, France. 1990: Auriault C; Gras-Masse H; Pierce R J; Butterworth A E; Wolowczuk I; Capron M; Ouma J H; Balloul J M; Khalife J; Neyrinck J LAntibody response of Schistosoma mansoni-infected human subjects to the recombinant P28 glutathione-S-transferase and to synthetic peptides.Journal of clinical microbiology 1990;28(9):1918-24.Centre d'Immunologie et de Biologie Parasitaire, Institut Pasteur, Lille, France. 1990: Trottein F; Kieny M P; Verwaerde C; Torpier G; Pierce R J; Balloul J M; Schmitt D; Lecocq J P; Capron AMolecular cloning and tissue distribution of a 26-kilodalton Schistosoma mansoni glutathione S-transferase.Molecular and biochemical parasitology 1990;41(1):35-44.Centre d'Immunologie et de Biologie Parasitaire, Unité Mixte INSERM 167-CNRS 624, Institut Pasteur, Lille, France. 1989: Loison G; Vidal A; Findeli A; Roitsch C; Balloul J M; Lemoine YHigh level of expression of a protective antigen of schistosomes in Saccharomyces cerevisiae.Yeast (Chichester, England) 1989;5(6):497-507.Transgene S.A., Strasbourg, France. 1989: Gruart V; Balloul J M; Prin L; Tomassini M; Loiseau S; Capron A; Capron MVariations in protein expression related to human eosinophil heterogeneity.Journal of immunology (Baltimore, Md. : 1950) 1989;142(12):4416-21.Centre d'Immunologie et de Biologie Parasitaire, Unité Mixte INSERM 167-CNRS, Lille, France. 1989: Wolowczuk I; Auriault C; Gras-Masse H; Vendeville C; Balloul J M; Tartar A; Capron AProtective immunity in mice vaccinated with the Schistosoma mansoni P-28-1 antigen.Journal of immunology (Baltimore, Md. : 1950) 1989;142(4):1342-50.Centre d'Immunologie et de Biologie Parasitaire, Institut Pasteur, Lille, France. 1988: Auriault C; Gras-Masse H; Wolowczuk I; Pierce R J; Balloul J M; Neyrinck J L; Drobecq H; Tartar A; Capron AAnalysis of T and B cell epitopes of the Schistosoma mansoni P28 antigen in the rat model by using synthetic peptides.Journal of immunology (Baltimore, Md. : 1950) 1988;141(5):1687-94.Centre d'Immunologie et de Biologie Parasitaire, Unité Mixte INSERM 167-CNRS 624, Lille, France. 1988: Taylor J B; Vidal A; Torpier G; Meyer D J; Roitsch C; Balloul J M; Southan C; Sondermeyer P; Pemble S; Lecocq J PThe glutathione transferase activity and tissue distribution of a cloned Mr28K protective antigen of Schistosoma mansoni.The EMBO journal 1988;7(2):465-72.Department of Biochemistry, Middlesex Hospital Medical School, London, UK. 1988: Jouault T; Capron M; Balloul J M; Ameisen J C; Capron AQuantitative and qualitative analysis of the Fc receptor for IgE (Fc epsilon RII) on human eosinophils.European journal of immunology 1988;18(2):237-41.Unité Mixte INSERM, Institut Pasteur, Lille, France. 1987: Capron A; Pierce R; Balloul J M; Grzych J M; Dissous C; Sondermeyer P; Lecocq J PProtective antigens in experimental schistosomiasis.Acta tropica. Supplementum 1987;12():63-9. 1987: Balloul J M; Grzych J M; Pierce R J; Capron AA purified 28,000 dalton protein from Schistosoma mansoni adult worms protects rats and mice against experimental schistosomiasis.Journal of immunology (Baltimore, Md. : 1950) 1987;138(10):3448-53. 1987: Auriault C; Balloul J M; Pierce R J; Damonneville M; Sondermeijer P; Capron AHelper T cells induced by a purified 28-kilodalton antigen of Schistosoma mansoni protect rats against infection.Infection and immunity 1987;55(5):1163-9. 1987: Balloul J M; Sondermeyer P; Dreyer D; Capron M; Grzych J M; Pierce R J; Carvallo D; Lecocq J P; Capron AMolecular cloning of a protective antigen of schistosomes.Nature 1987;326(6109):149-53. 1987: Pierce R J; Balloul J M; Grzych J M; Dissous C; Auriault C; Boulanger D; Capron M; Sondermeyer P; Lecocq J P; Capron AGP38, P28-I and P28-II: candidates for a vaccine against schistosomiasis.Memórias do Instituto Oswaldo Cruz 1987;82 Suppl 4():111-4.Centre d'Immunologie et de Biologie Parasitaire, Institut Pasteur, Lille, France. 1985: Balloul J M; Pierce R J; Grzych J M; Capron AIn vitro synthesis of a 28 kilodalton antigen present on the surface of the schistosomulum of Schistosoma mansoni.Molecular and biochemical parasitology 1985;17(1):105-14. 1985: Pierce R J; Aimar C; Balloul J M; Delarue M; Grausz D; Verwaerde C; Capron ATranslation of Schistosoma mansoni antigens in Xenopus oocytes microinjected with mRNA from adult worms.Molecular and biochemical parasitology 1985;15(2):171-88.

Anual Salary